Lb Pharmaceuticals (LBRX) Current Assets (2024 - 2026)

Lb Pharmaceuticals has reported Current Assets for 3 years, with the latest figure at $389.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets changed N/A year-over-year to $389.1 million; the trailing twelve-month figure through Mar 2026 stood at $389.1 million (changed N/A YoY), and the FY2025 full-year result was $308.4 million, up 968.01% from the prior year.
• Current Assets for Q1 2026 stood at $389.1 million, up from $308.4 million in the prior quarter.
• The five-year high for Current Assets was $389.1 million in Q1 2026, with the low at $28.9 million in Q4 2024.
• Average Current Assets over 3 years is $260.7 million, with a median of $312.4 million recorded in 2025.
• Peak annual rise in Current Assets reached 968.01% in 2025, while the deepest fall reached 968.01% in 2025.
• Tracing LBRX's Current Assets over 3 years: stood at $28.9 million in 2024, then jumped by 968.01% to $308.4 million in 2025, then gained by 26.15% to $389.1 million in 2026.
• The last three Current Assets figures came in at $389.1 million (Q1 2026), $308.4 million (Q4 2025), and $316.4 million (Q3 2025), per Business Quant data.

Peer Comparison